Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript

Daniel Vitt: Thanks, Jessica, and thank you to today’s attendees for your insightful questions. To summarize, with the positive interim data from our Phase II CALLIPER trial as well as the continuation of enrollment of our Phase III ENSURE trials, we continue to make tangible progress on the clinical development of vidofludimus calcium. As progress is made, we also expect to provide an update on our preparations for further Phase II clinical development of IMU-856. With our funds at the end of the fourth quarter and the recent closing of the first tranche of our three-tranche private placement, we remain well funded, providing us runway through multiple clinical milestones into the third quarter of 2025. With that, I would like to close today’s call. Thank you very much for joining, and we are very happy to answer any additional questions one-on-one.

Jessica Breu: Thank you, Daniel, and thank you for joining Immunic Fourth Quarter and Year End 2023 Earnings Call. The call has now concluded. You may now disconnect.